nach oben

BioDrugs

Erschienen in:

01.05.2002 | Adis R&d Profile

Prostate Cancer Vaccine — Northwest Biotherapeutics

CaPVax, DC1/HRPC, DCVax — Prostate

Erschienen in: BioDrugs | Ausgabe 3/2002

Einloggen, um Zugang zu erhalten

Excerpt

Northwest Biotherapeutics is developing a prostate cancer vaccine based on its proprietary dendritic-cell based vaccine technology (DCVax™).¹ The vaccine (DCVax™-Prostate, CaPVax, DC1/HRPC) consists of prostate-specific membrane antigen (PSMA)-pulsed autologous dendritic cells and is in phase III development in the USA. …

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Wang L, Elgamal A, Shankar G, et al. rPSMA-Loaded autologous dendritic cell vaccine (CaPVax) safely activates cellular and humoral immune responses against androgen-independent prostate cancer. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12; San Francisco, 20(2): 222

Shankar G, Kelley H, Lodge A, et al. Monitoring immune responses of prostate cancer patients vaccinated with prostate-specific membrane antigen (PSMA) protein-loaded dendritic cells in a phase I/II clinical trial. 92nd Annual Meeting of the American Association for Cancer Research; 2001 Mar 24–28; New Orleans, 42: 26–7

Salgaller ML, Lodge PA, Bader RR, et al. Monitoring the immune reactivity of prostate cancer patients vaccinated with dendritic cells expressing prostate-specific membrane antigen peptides during a phase II clinical trial. 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10; Philadelphia, 576

Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999 Jul 1; 40: 125–9PubMedCrossRef

Simmons SJ, Tjoa BA, Rogers M, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999 Jun 1; 39: 291–7PubMedCrossRef

Lodge PA, Jones LA, Bader RA, et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000 Feb 15; 60: 829–33PubMed

Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996 Jun; 29: 371–80PubMedCrossRef

Northwest Biotherapeutics Inc. Northwest Biotherapeutics, Inc. to present new phase I/II clinical data on promising prostate cancer treatment [media release 2002 Mar 5]. Available from URL: http://www.nwbio.com [Accessed 2002 July 2]

Titel: Prostate Cancer Vaccine — Northwest Biotherapeutics
CaPVax, DC1/HRPC, DCVax — Prostate
Publikationsdatum: 01.05.2002
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 3/2002
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200216030-00010

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Prostate Cancer Vaccine — Northwest Biotherapeutics

CaPVax, DC1/HRPC, DCVax — Prostate

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2002

Waldenström’s Macroglobulinaemia

CellControl AG

Gastric Inhibitory Polypeptide Analogues

Exendin 4

Human Haemoglobin — Hemosol

Spotlight on Peginterferon-α-2a (40KD) in Chronic Hepatitis C